anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to a medical composition of a beta-cyclodextrin or amoxycillin inclusion compound, which is prepared from amoxycillin and beta-cyclodextrin, wherein the mass ratio of the amoxycillin to the beta-cyclodextrin is from 1:2.5 to 1:5. The medical composition has the optimized scheme that the medical composition also comprises potassium clavulanate, and the mass ratio of the amoxycillin to the potassium clavulanate is from 14:1 to 2:1. Auxiliary materials are selected from microcrystalline cellulose, cornstarch, citric acid, talcum powder, sodium carboxyl methylstarch, stearic acid, calcium stearate, magnesium stearate, pregelatinized starch, lactose, mannitol, polyvinylpolypyrrolidone, polyethyleneglycol 4000, low-substitution hydroxypropyl cellulose, etc. The preparation method comprises: the beta-cyclodextrin is mixed with water for forming a suspension body; 1/5 to 2/5 of amoxycillin by mass is added to the suspension body, and the mixture is sufficiently mixed and ground; the mixture is cooled and filtered; after being washed with water, a solid substance is dried; and the solid inclusion compound is obtained. The medical composition greatly improves and strengthens the stability, the machining property and the dissolution characteristic of amoxycillin. The compatibility of the amoxycillin with the potassium clavulanate improves the pharmaceutical performance of the medical composition.
Herbal medicine (dian dao san) will be applied to the lesions of rosacea twice a day. Subject will receive persistent treatment for 6 weeks.
Lidocaine Hydrochloride Topical Solution, USP contains a local anesthetic agent and is administered topically. See INDICATIONS for specific uses.

Each mL contains:

Methylparaben, sodium hydroxide (to adjust pH) in an aqueous solution. NOT FOR INJECTION.

Lidocaine is a local anesthetic chemically designated as 2-(diethylamino)-N-(2,6-dimethylphenyl) acetamide monohydrochloride, monohydrate. It has the following structural formula:
PURPOSE:To produce capsules having an uniform wall thickness in a short time, by using a simple substance of gelan gum or with other colloids. CONSTITUTION:0.5-4pts. gelan gum which is one kind of polysaccharides or, if necessary, an adequate amount of other colloids, e.g. carrageenan or xanthan gum, or other solid components, e.g. sugar or dextrin, is dispersed in 100pts. hot water at >=90 deg.C and dissolved while stirring by a conventional method. The resultant solution is then used to produce capsules. Gelation temperature can be increased as compared with that of gelatin and gelation rate can be increased.
The pilot study consists of two research scenarios, in which two different sequences of the interventions taking the form of the pre-programmed tilt and LBNP profiles are to be investigated.

1. Scenario I is designed to initially verify the potential impact of the prototype system on the human body. For this purpose, only basic tilt and LBNP stimuli of relatively slowly increasing intensities will be used, and the group of subjects will include only subjects with flight experience. Up to 20 PAFA cadets shortly before graduation, including women and men, will be involved in the pilot study (experimental arm 1). The subjects will be healthy, aged between 20 and 30 years old. Scenario I will take almost 24 min.
2. Scenario II is to compare subjects with and without flight experience using rapid tilt and LBNP stimuli as well as a push-pull stimulus. Up to 30 subjects including up to 15 pilots, i.e., flight school adepts shortly after graduation and/or PAFA cadets shortly before graduation, and up to 15 students of the Aviation High School in Dęblin, Poland, including women and men will be involved in the study (experimental arm 2). The subjects will be healthy, aged between 18 and 30 years old. The students of the Aviation High School will participate in the study as a reference group, without flight experience. Scenario II will take 16 min.

The pilot study will be carried out in an isolated room in the presence of a physician (physiologist), a paramedic and an ORTHO-LBNP system operator. The paramedic will prepare the subject for the study by placing on his/her body electrodes and measuring sensors that will be removed after completion of the study. The subject will be asked to close his/her eyes during the tests and to place his/her hands on the rest. In order to cause the least disturbance, no conversation will be held with the subject. Only if disturbing symptoms will occur, will the subject immediately report this to the personnel. The physician will systematically be observing the subject's cardiogram, his/her HR, continuous non-invasive arterial pressure (CNAP) wave, and systolic and diastolic blood pressure (SBP and DBP, respectively) in comparison with the changing tilt of the table and negative pressure in the chamber. Any time, at the request of the subject or on the instruction of the physician, the operator will interrupt the tests. The tilt table then will return to the Trendelenburg position if interruption occur during HUT and/or LBNP stimuli, or horizontal position if interruption occur during HDT stimulus. At the same time atmospheric pressure will be resumed in the chamber.
Treatment at trauma centers improves outcomes for patients with moderate-to-severe injuries. Accordingly, professional organizations, state authorities, and the federal government have endorsed the systematic triage and transfer of these patients to trauma centers either directly from the field or after evaluation at a non-trauma center. Nonetheless, between 30 to 40% of patients with moderate-to-severe injuries still only receive treatment at non-trauma centers, so-called under-triage. Most of this under-triage occurs because of physician decisions (rather than first-responder decisions). Existing efforts to change physician decision making focus primarily on knowledge of clinical practice guidelines and attitudes towards the guidelines. These strategies ignores the growing consensus that decision making reflects both knowledge as well as intuitive judgments (heuristics). Heuristics, mental short cuts based on pattern recognition, drive the majority of decision making. The investigators have developed an adventure video game (Night Shift) to serve as a novel method of recalibrating physician heuristics in trauma triage and will compare its efficacy with a standard educational program.
Women who are being pregnant and plan to give birth in local hospital. Pregnant women who plan to stay in the same local area for at least 7 years post-delivery.
The energetic excitation of biological pharmaceuticals comprises irradiating the active ingredient or its soln., either at rest or circulating. Irradiation is in a cell or chamber of quartz or with a quartz window, and uses wavelengths or frequencies which correspond to the absorption or emission spectrum of the substances or substance mixt. Coherent and non-stochastic radiation is used with or without simultaneous application of a magnetic field parallel or perpendicular to the direction of radiation. The process activates the medical effect of the drugs, and is esp. suitable for activating organotherapeutics, phytotherapeutics and prepns. for microorganisms, vitamins, ferments, enzymes and hormones can be treated by this method, which is esp. suitable for macromolecular organ extracts obtd. by a special process for controlled chemical decomposition of biological tissues using the vapour of chemical reagents.
Non-invasive, visual, and quantitative in vivo evaluation of pulmonary blood flow is helpful in assessing gas exchange at the alveolar level. A chest digital dynamic radiography system (CDDR) has the potential to visually and quantitatively express pulmonary haemodynamics using temporal changes in radiographic transparency synchronised with the heartbeat. The lung-diffusing capacity (DLCO) test involves membranous factors comprising the alveolar membrane, interstitium, and vascular walls. Additionally, DLCO includes pulmonary blood flow factors defined by pulmonary capillary blood flow and haemoglobin levels. In individuals lacking an alveolar septum, interstitial abnormalities or anaemia leading to changes in DLCO may reflect changes in the pulmonary blood flow. Here, we investigated the usefulness of CDDR in evaluating pulmonary blood flow by comparing it with DLCO.For pulmonary blood flow, we extracted and visualised signal changes in the lung field synchronised with heart rate during CDDR imaging and created a maximum intensity projection (MIP). The DLCO was measured using the single-breath method. Among the patients who underwent CDDR, 10 with FEV/FVC (FEV1.0%) > 70% and 16 with COPD (FEV1.0% < 70%) without noticeable interstitial changes were included, with a cutoff = 70%/predicted value. MIP was compared as a pulmonary blood flow evaluation method in the DLCO≥70% group (control group: n = 15) and the DLCO<70% group (decreased DLCO group: n = 11). The mean and median values of MIP in the reduced group were lower than those in the control group (p < 0.05).Pulmonary blood flow evaluated using CDDR may be able to assess pulmonary circulatory disturbances visually and quantitatively, as indicated by decreased pulmonary diffusion capacity in patients with negligible pulmonary interstitial changes and anaemia.
Systemic lupus erythematosus (SLE) is a rare chronic autoimmune disease (1/2000 inhabitants) that evolves in periods of recurrent remissions. Sufferers are most often young women of childbearing age. SLE affects the life of a couple like family life (financial, emotional, relational or sexual conditions of the couple). In addition, the disease and its treatments can hinder the possibility of building a family project (pregnancy).

The purpose of the Psy-LUP study is to study the impact of SLE on the social participation of patients, that is to say on their ability to get involved in different areas of daily life. These repercussions could be all the more important as lupus disease is active and complicated by severe diseases such as kidney disease. We want to study how sick people and their loved ones (spouse in particular) think about lupus disease, how it fits into their life history, how people have adapted to this disease, and how it affects their lives. could have on their social participation, their social support, their life of couple. The Psy-LUP study will be carried out in different care services, and by telephone interviews at home, with two main axes: (1) a study by questionnaire with patients (n = 100); (2) a qualitative study through research interviews with patients (n = 40) and their spouses (n = 20). The realization of this project will allow us to evaluate and understand the impact of SLE on the life of the couple and its relational and affective components. In addition, the Psy-LUP study will describe the representations that sick people and their relatives have of lupus disease. All the data collected will make it possible to target interventions with 1) patients and their relatives, in terms of therapeutic education, psychosocial support, support groups (associations); 2) caregivers caring for people with SLE, so that they can integrate the issues of the patient's experience in their care practice and their reflection on therapeutic strategies.
Comparison control families meet with the Study Physician and a Registered Dietitian as a family to review laboratory results and receive lifestyle counseling. Control families will be contacted on a monthly basis for a total of 12 months.
Death has been reported in children who have accidentally ingested transmucosal immediate–release fentanyl products.

Patients and their caregivers must be informed that SUBSYS contains a medicine in an amount which can be fatal to a child. Physicians and dispensing pharmacists must specifically question patients or caregivers about the presence of children in the home (on a full time or visiting basis) and counsel them regarding the dangers to children from inadvertent exposure. 

Patients and their caregivers must be instructed to keep both used and unused dosage units out of the reach of children. While all units should be disposed of immediately after use, partially consumed units represent a special risk to children. In the event that a unit is not completely consumed it must be properly disposed as soon as possible [ see Patient Counseling Information ( 17) ]. 

Detailed instructions for the proper storage, administration, disposal, and important instructions for managing an overdose of SUBSYS are provided in the SUBSYS Medication Guide. Encourage patients to read this information in its entirety and give them an opportunity to have their questions answered.
The present invention belongs to the technical field of medicine. The present invention relates to high-molecular medicine for suppressing tumor metastasis, which comprises carboxylic acid and imide radicals, and a preparation method thereof. Tumor cells not only damage tissues at a primary focus, but also frequently transfer to healthy tissues so as to cause secondary tumors. The second case is an important reason that tumors can not be fundamentally cured, the present invention adopts a type of polymer which comprises carboxylic acid base groups and imide base groups. A medicine molecular design is carried out by selecting replaceable base groups. Thus, the high-molecular medicine with low toxicity and obvious suppressing effect on tumor metastasis is obtained.
PURPOSE:To obtain a safe bronchodilator useful for treating chronic closed air duct diseases, having bronchodilating action, comprising a pyridine derivative or an acid addition salt thereof as an active ingredient. CONSTITUTION:A bronchodilator comprising a pyridine derivative shown by the formula or a pharmaceutically acceptable acid addition salt thereof (e.g. hydrochloride or hydrobromide) as an active ingredient. Action mechanism of the bronchodilator is that the bronchodilator directly relaxes smooth muscle of bronchial tubes, suppresses rise in resistance caused by constriction of air duct and alleviates dyspnea. The compound shown by the formula has excellent bronchodilating action. The compound can be administered orally or parenterally. A dose is usually 100-2,000mg per adult daily in the case of oral administration.
Prophylactic Usage

Safety and efficacy of griseofulvin for prophylaxis of fungal infections have not been established.

Serious Skin Reactions

Severe skin reactions (e.g., Stevens-Johnson syndrome, toxic epidermal necrolysis) and erythema multiforme have been reported with griseofulvin use. These reactions may be serious and may result in hospitalization or death. If severe skin reactions occur, griseofulvin should be discontinued (see ADVERSE REACTIONS section).

Hepatotoxicity

Elevations in AST, ALT, bilirubin, and jaundice have been reported with griseofulvin use. These reactions may be serious and may result in hospitalization or death. Patients should be monitored for hepatic adverse events and discontinuation of griseofulvin considered if warranted (see ADVERSE REACTIONS section).

Animal Toxicology

Chronic feeding of griseofulvin, at levels ranging from 0.5% to 2.5% of the diet resulted in the development of liver tumors in several strains of mice, particularly in males. Smaller particle sizes result in an enhanced effect. Lower oral dosage levels have not been tested. Subcutaneous administration of relatively small doses of griseofulvin once a week during the first three weeks of life has also been reported to induce hepatomata in mice. Thyroid tumors, mostly adenomas but some carcinomas, have been reported in male rats receiving griseofulvin at levels of 2.0%, 1.0% and 0.2% of the diet, and in female rats receiving the two higher dose levels. Although studies in other animal species have not yielded evidence of tumorigenicity, these studies were not of adequate design to form a basis for conclusion in this regard. In subacute toxicity studies, orally administered griseofulvin produced hepatocellular necrosis in mice, but this has not been seen in other species. Disturbances in porphyrin metabolism have been reported in griseofulvin-treated laboratory animals. Griseofulvin has been reported to have a colchicine-like effect on mitosis and cocarcinogenicity with methylcholanthrene in cutaneous tumor induction in laboratory animals.

Usage in Pregnancy \- see CONTRAINDICATIONS section.

Animal Reproduction Studies

It has been reported in the literature that griseofulvin was found to be embryotoxic and teratogenic on oral administration to pregnant rats. Pups with abnormalities have been reported in the litters of a few bitches treated with griseofulvin. Suppression of spermatogenesis has been reported to occur in rats, but investigation in man failed to confirm this.
Implantable Defibrillators (ICDs) reduce sudden death and can terminate some VT without shocks, but they don't prevent VT; the most appropriate strategy to suppress VT remains unknown. Two randomized clinical trials have suggested that catheter ablation can significantly reduce the incidence of subsequent VT in patients after an initial episode. Neither trial, however, compared catheter ablation to active antiarrhythmic drug therapy. Randomized trials of antiarrhythmic drug therapy have demonstrated that therapy with either sotalol or amiodarone can reduce recurrent VT. Both antiarrhythmic drug and ablation therapy suffer from imperfect efficacy and the potential for significant side-effects. No study has compared ablation to drug therapy for first-line treatment. The VANISH study which compared ablation to aggressive antiarrhythmic drug therapy for patients who have failed initial drug therapy was published in May 2016, and demonstrated that for patients with drug-refractory VT, catheter ablation was superior to escalation of antiarrhythmic drug therapy. Benefits were seen in the group which had VT despite amiodarone. Event rates were similar between amiodarone and sotalol for patients with VT occurring despite sotalol, who were randomized to either new initiation of amiodarone or catheter ablation. These results do not address the clinical question of the most appropriate first line therapy for suppression of VT in persons with prior myocardial infarction, an ICD and VT.

The trial hypothesis is: catheter ablation will, in comparison to antiarrhythmic drug therapy reduce the composite outcome of death at any time, appropriate ICD shock after 14 days, ventricular tachycardia storm after 14 days or treated sustained ventricular tachycardia below the detection rate of the ICD for patients with prior myocardial infarction and sustained monomorphic ventricular tachycardia.
PROBLEM TO BE SOLVED: To obtain an apoptosis regulator useful for treating infectious diseases, immunopathy, malignant tumor, etc., by using a specific cinnamic acid derivative obtained from a natural extract, especially a propolis extract as an active ingredient. SOLUTION: This apoptosis regulator comprises a 3-[4-hydroxy-3,5-bis(3- methyl-2-butenyl)phenyl]-2-propenoic acid of the formula (X is a physiologically permissible cation) and/or its physiologically permissible salt (a salt such as Na, K, Ca or Mg is especially preferred) as an active ingredient. The compound is preferably derived from propolis. The active ingredient in an amount of preferably >=0.01wt.% is contained in the apoptosis regulator. Since the active ingredient is readily oxidized, the use thereof together with an antioxidant usually blended in a food, a cosmetic or a medicine is preferred. The content of the antioxidant is preferably 0.01-10wt.%.
This arm of the study receives a 10-session online family-based intervention with separate, but intersecting, tracks for parents and youth. Each lesson contains 3 mini-lessons per week and includes behavioral skills training and interactive multimedia lessons with video vignettes that target parenting skills, family cohesion, organization, communication, social skills, and drug prevention for youth. The youth track is highly gamified to stimulate engagement and reinforce the core active ingredients. There are self-correcting quizzes to assess learning, and process evaluation to determine program fidelity and engagement. There are learning theory instructional design elements with scaffolding, stealth learning, and theoretical principles of social learning, social interactional, and family systems theory. There is a highly animated game families can play upon successful completion of each lesson, using game points they earned through quizzes and practices. There is a 3-month follow-up.
Methodology This study will be a retrospective study using administrative and clinical patient data of patients presenting for alcohol detoxification at the Psychiatry department of the Universitair Ziekenhuis Brussel. Two periods in the data will be compared. One period will be consisting of patient data before 2013 when the hospital still used the fixed-schedule dosing of benzodiazepines. The other period will be consisting of patient data after 2013 when the hospital switched to the symptom-triggered prescription of benzodiazepines.

Inclusion \& Exclusion criteria Inclusion criteria are patients with the age of 18 years or older who were treated for alcohol .dependence at the UZ Brussel in one of the periods stated above. The criteria for exclusion were found in the literature and include pregnancy, use of central nervous system (CNS) depressant agents, history of dementia, acute psychosis, and severe hepatic dysfunction (15-18). Comorbid benzodiazepine dependence. A history of severe epilepsy on withdrawal,... Outcomes The main outcome measures will be the total amount of benzodiazepines given during the hospital stay, whether the patient is still dependent on benzodiazepines when leaving the hospital, the length of the hospital stay, and some baseline patient characteristics. These patient characteristics will include age, sex, race/ethnic group, primary reason for hospitalization, body mass index (BMI), blood alcohol level (BAL) on admission, international normalized ratio (INR), diagnosis of co-morbid psychiatric disorder, history of other substance abuse, indicators of withdrawal severity (e.g. CIWA-Ar, tremor, seizures), discharge medications, benzodiazepine dose administered (15-18).
PURPOSE:A multilocular soft capsule agent, obtained by dividing the interior of a soft capsule with a partition film, capable of incorporating stably even with incompatible drugs, and having improved effect such as an enteric part of one soft capsule agent and the other disintegrable in the intestines, etc. CONSTITUTION:A multilocular soft capsule agent obtained by dividing the interior of an oval soft capsule formed by the upper film (1a) and the lower film (1b) into two chambers with a partition film 2. A drug (3a) is filled in the upper chamber consisting of the upper film (1a) and the partition film 2, and a drug (3b) is filled in the lower chamber consisting of the lower film (1b) and the partition film 2. Incompatible drugs are separated by the partition film 2, and can be stably incorporated in one soft capsule agent. Part of the one soft capsule agent is enteric, and the other part is disintegrable in the intestines. Alternatively, the capsule can be partially rapid acting, and the other part can be slow acting. The aimed soft capsule agent can be produced by applying the conventional plate method, etc. for the soft capsule agent.